Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PolaR-ICE as Initial Salvage Therapy for Relapsed/Refractory DLBCL
NCT04665765Phase 2Active, not recruiting
- Sponsor
- City of Hope
- Start
- Jan 2021
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of polatuzumab vedotin in diffuse large B-cell lymphoma (DLBCL), sponsored by City of Hope. Primary endpoints: Complete Response Rate at 6 weeks, Number of Unacceptable Toxicities (Phase 2 Stage) at 6 weeks and 1 more. Started Jan 2021; status: active, not recruiting.
02
Drugs
polatuzumab vedotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04665765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04665765.